成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. NF-κB Anti-infection Autophagy
  2. NF-κB SARS-CoV Influenza Virus Autophagy Parasite
  3. Andrographolide

Andrographolide  (Synonyms: 穿心蓮內(nèi)酯; Andrographis)

目錄號(hào): HY-N0191 純度: 99.89%
COA 產(chǎn)品使用指南 技術(shù)支持

Andrographolide 是一種 NF-κB 抑制劑,通過(guò)共價(jià)修飾內(nèi)皮細(xì)胞中 p50 的半胱氨酸殘基而抑制 NF-κB 活化,而不影響 IκBα 降解或 p50/p65 核易位。Andrographolide 具有抗病毒作用。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Andrographolide Chemical Structure

Andrographolide Chemical Structure

CAS No. : 5508-58-7

1.  客戶(hù)無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機(jī)構(gòu)(單位)一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶(hù)。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥385
In-stock
100 mg ¥350
In-stock
500 mg ¥1244
In-stock
1 g   詢(xún)價(jià)  
5 g   詢(xún)價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Andrographolide:

    Andrographolide purchased from MCE. Usage Cited in: Front Microbiol. 2018 Oct 8;9:2407.  [Abstract]

    RD cells are pretreated with andrographolide or DMSO vehicle overnight and subsequently infected with EV-D68. Immunoblotting of VP1 expression at 2, 4, 8, 12 h post-infection. There is an observable reduction in EV-D68 VP1 protein expression in ADO-treated cells compared to vehicle-treated cells on immunoblotting.

    Andrographolide purchased from MCE. Usage Cited in: Front Microbiol. 2018 Oct 8;9:2407.  [Abstract]

    Fluorescence intensity peaked at around 2 h post-infection and is quickly quenched by 3 h post-infection in vehicle-treated RD cells. ADO-treated cells exhibit limited fluorescence.

    Andrographolide purchased from MCE. Usage Cited in: Front Microbiol. 2018 Oct 8;9:2407.  [Abstract]

    Immunofluorescence of VP1 expression at 10 h post-infection. There is an observable reduction in EV-D68 VP1 protein expression in ADO-treated cells compared to vehicle-treated cells on immunofluorescence assays
    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.

    IC50 & Target[1]

    p50

     

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A2058 IC50
    26 μM
    Compound: 4; AGL
    Cytotoxicity against human A2058 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human A2058 cells incubated for 48 hrs by MTT assay
    [PMID: 33289552]
    A549 IC50
    12.15 μM
    Compound: 1
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay
    [PMID: 33316411]
    A549 GI50
    13.37 μM
    Compound: 1
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    [PMID: 23768904]
    A549 IC50
    27.9 μM
    Compound: 1
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by SRB assay
    [PMID: 28755636]
    A549 IC50
    32.02 μM
    Compound: 1
    Anticancer activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Anticancer activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    [PMID: 32527561]
    A549 IC50
    9.71 μg/mL
    Compound: 1
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    10.1039/C4MD00566J
    ACHN IC50
    3.03 μg/mL
    Compound: 1
    Cytotoxicity against human ACHN cells by MTT assay
    Cytotoxicity against human ACHN cells by MTT assay
    10.1039/C4MD00566J
    B16 IC50
    7.54 μg/mL
    Compound: 1
    Cytotoxicity against mouse B16 cells by MTT assay
    Cytotoxicity against mouse B16 cells by MTT assay
    10.1039/C4MD00566J
    BMDM IC50
    0.55 μM
    Compound: AM-721/20681006
    Inhibition of GST-tagged recombinant RANKL/M-CSF-induced osteoclastogenesis in C57BL/6 mouse bone marrow derived macrophages assessed as TRAcP enzymatic activity incubated for 5 days with subsequent replenishment of media for 2 days and measured by leucoc
    Inhibition of GST-tagged recombinant RANKL/M-CSF-induced osteoclastogenesis in C57BL/6 mouse bone marrow derived macrophages assessed as TRAcP enzymatic activity incubated for 5 days with subsequent replenishment of media for 2 days and measured by leucoc
    [PMID: 33158578]
    BMMC IC50
    1.01 μM
    Compound: 1; AP
    Anti-osteoporosis activity in C57BL/6 mouse BMM cells assessed as inhibition of M-CSF/RANKL-induced osteoclastogenesis by measuring reduction in multinucleated TRAP+ cells incubated for 5 days with media replenishment for every 48 hrs measured by TRAP-sta
    Anti-osteoporosis activity in C57BL/6 mouse BMM cells assessed as inhibition of M-CSF/RANKL-induced osteoclastogenesis by measuring reduction in multinucleated TRAP+ cells incubated for 5 days with media replenishment for every 48 hrs measured by TRAP-sta
    [PMID: 33485256]
    BMMC CC50
    10.31 μM
    Compound: 1; AP
    Cytotoxicity against C57BL/6 mouse BMM cells assessed as reduction in cell viability measured after 48 hrs in presence of M-CSF by CCK8 assay
    Cytotoxicity against C57BL/6 mouse BMM cells assessed as reduction in cell viability measured after 48 hrs in presence of M-CSF by CCK8 assay
    [PMID: 33485256]
    Col2 ED50
    13.6 μM
    Compound: 1
    Cytotoxicity against human Col2 cells by SRB assay
    Cytotoxicity against human Col2 cells by SRB assay
    [PMID: 22154665]
    DU-145 GI50
    15.99 μM
    Compound: 1
    Growth inhibition of human DU145 cells after 72 hrs by SRB assay
    Growth inhibition of human DU145 cells after 72 hrs by SRB assay
    [PMID: 23768904]
    HCT-116 IC50
    23.93 μM
    Compound: 1
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay
    [PMID: 23628335]
    HCT-116 IC50
    31.8 μM
    Compound: Andrographolide
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    [PMID: 34315039]
    HCT-116 GI50
    4.5 μM
    Compound: 21; AGP
    Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition measured after 96 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition measured after 96 hrs by MTT assay
    [PMID: 33228976]
    HEK293 CC50
    26.25 μM
    Compound: 1
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-glo assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-glo assay
    [PMID: 32712435]
    HEK293 IC50
    49.6 μM
    Compound: 1
    Inhibition of TNF-alpha-stimulated NF-kappaB p50 (unknown origin) expressed in HEK293 cells preincubated for 4 hrs followed by TNF-alpha challenge measured after 24 hrs by secreted alkaline phosphatase reporter assay
    Inhibition of TNF-alpha-stimulated NF-kappaB p50 (unknown origin) expressed in HEK293 cells preincubated for 4 hrs followed by TNF-alpha challenge measured after 24 hrs by secreted alkaline phosphatase reporter assay
    [PMID: 25615020]
    HeLa IC50
    10.42 μg/mL
    Compound: 1
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    10.1039/C4MD00566J
    HeLa IC50
    23 μM
    Compound: Andrographolide
    Antiviral activity against DENV2 infected in human HeLa cells incubated for 1 hrs by plaque assay
    Antiviral activity against DENV2 infected in human HeLa cells incubated for 1 hrs by plaque assay
    [PMID: 34315039]
    HepG2 IC50
    21 μM
    Compound: Andrographolide
    Antiviral activity against DENV2 infected in human HepG2 cells incubated for 1 hrs by plaque assay
    Antiviral activity against DENV2 infected in human HepG2 cells incubated for 1 hrs by plaque assay
    [PMID: 34315039]
    HepG2 IC50
    9.7 μM
    Compound: 1
    Antagonist activity at Gal4 DBD-fused human FXR LBD expressed in human HepG2 cells after 8 hrs by luciferase reporter gene assay
    Antagonist activity at Gal4 DBD-fused human FXR LBD expressed in human HepG2 cells after 8 hrs by luciferase reporter gene assay
    [PMID: 31151068]
    HepG2 2.2.15 CC50
    198 μM
    Compound: 1b
    Cytotoxicity against human HepG2.2.15 cells by MTT assay
    Cytotoxicity against human HepG2.2.15 cells by MTT assay
    [PMID: 24731274]
    HL-60 IC50
    2.4 μM
    Compound: 4; AGL
    Antiproliferative activity against human HL-60 cells incubated for 24 hrs by MTT assay
    Antiproliferative activity against human HL-60 cells incubated for 24 hrs by MTT assay
    [PMID: 33289552]
    HL-60 IC50
    27 μM
    Compound: 6
    Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry
    Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry
    [PMID: 22985027]
    HL-60 GI50
    9.33 μM
    Compound: 7
    Antiproliferative activity against human HL60 cells by trypan blue assay
    Antiproliferative activity against human HL60 cells by trypan blue assay
    [PMID: 18357994]
    HT-29 IC50
    > 30 μM
    Compound: 4; AGL
    Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay
    [PMID: 33289552]
    HT-29 IC50
    10.8 μM
    Compound: 1
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay
    [PMID: 33316411]
    HT-29 IC50
    8.91 μM
    Compound: 1
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Anticancer activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    [PMID: 32527561]
    HT-29 IC50
    9.34 μM
    Compound: 1
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by SRB assay
    [PMID: 28755636]
    HuCC-A1 IC50
    23.61 μM
    Compound: 1
    Anticancer activity against human HuCCa1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Anticancer activity against human HuCCa1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    [PMID: 32527561]
    IEC-6 IC50
    8.26 μg/mL
    Compound: 1
    Cytotoxicity against rat IEC-6 cells by MTT assay
    Cytotoxicity against rat IEC-6 cells by MTT assay
    10.1039/C4MD00566J
    K562 IC50
    23.66 μM
    Compound: Andrographolide
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay
    [PMID: 34315039]
    K562 IC50
    41.85 μM
    Compound: Andrographolide
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    [PMID: 20974534]
    KB GI50
    13.18 μM
    Compound: 1
    Growth inhibition of human KB cells after 72 hrs by SRB assay
    Growth inhibition of human KB cells after 72 hrs by SRB assay
    [PMID: 23768904]
    KB IC50
    27.37 μM
    Compound: 1
    Cytotoxicity against human KB cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human KB cells assessed as reduction in cell viability by SRB assay
    [PMID: 28755636]
    KB ED50
    27.37 μM
    Compound: 1
    Cytotoxicity against human KB cells by SRB assay
    Cytotoxicity against human KB cells by SRB assay
    [PMID: 22154665]
    KB IC50
    31.73 μM
    Compound: 1
    Anticancer activity against human KB cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Anticancer activity against human KB cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    [PMID: 32527561]
    KB IC50
    41.53 μM
    Compound: 1
    Cytotoxicity against human KB cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human KB cells assessed as reduction in cell viability by SRB assay
    [PMID: 33316411]
    KBM5 IC50
    8.5 μM
    Compound: Andrographolide
    Antiproliferative activity against human KBM5 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human KBM5 cells assessed as reduction in cell viability by MTT assay
    [PMID: 34315039]
    L02 CC50
    14.68 μM
    Compound: 1
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-glo assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-glo assay
    [PMID: 32712435]
    L132 IC50
    53.8 μM
    Compound: Andrographolide
    Antiproliferative activity against human L-132 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    Antiproliferative activity against human L-132 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    [PMID: 20974534]
    Lu1 ED50
    12.98 μM
    Compound: 1
    Cytotoxicity against human Lu1 cells by SRB assay
    Cytotoxicity against human Lu1 cells by SRB assay
    [PMID: 22154665]
    MCF7 IC50
    > 66 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS assay
    [PMID: 23628335]
    MCF7 IC50
    15 μM
    Compound: 4; AGL
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
    [PMID: 33289552]
    MCF7 IC50
    15.4 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    [PMID: 28755636]
    MCF7 ED50
    15.4 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    [PMID: 22154665]
    MCF7 IC50
    29.06 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay
    [PMID: 33316411]
    MCF7 IC50
    30.82 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 25913115]
    MCF7 IC50
    8.48 μM
    Compound: 1
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    [PMID: 32527561]
    MDA-MB-231 IC50
    > 30 μM
    Compound: 4; AGL
    Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
    [PMID: 33289552]
    MDA-MB-231 IC50
    16.55 μM
    Compound: 1
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    [PMID: 25913115]
    NIH3T3 IC50
    44.5 μM
    Compound: Andrographolide
    Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    [PMID: 20974534]
    NIH3T3 IC50
    95.28 μM
    Compound: 1
    Antifibrotic activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Antifibrotic activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 30144698]
    NTUB1 IC50
    32.52 μM
    Compound: 1
    Cytotoxicity against human NTUB1 cells after 48 hrs by MTT assay
    Cytotoxicity against human NTUB1 cells after 48 hrs by MTT assay
    [PMID: 25913115]
    P388 IC50
    2.25 μM
    Compound: 1
    Cytotoxicity against mouse P388 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against mouse P388 cells assessed as reduction in cell viability by SRB assay
    [PMID: 28755636]
    P388 ED50
    2.25 μM
    Compound: 1
    Cytotoxicity against mouse P388 cells by SRB assay
    Cytotoxicity against mouse P388 cells by SRB assay
    [PMID: 22154665]
    P388 IC50
    6.52 μM
    Compound: 1
    Anticancer activity against mouse P388 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Anticancer activity against mouse P388 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    [PMID: 32527561]
    PC-3 IC50
    30 μM
    Compound: Andrographolide
    Growth inhibition of human PC3 cells after 48 hrs by MTT assay
    Growth inhibition of human PC3 cells after 48 hrs by MTT assay
    [PMID: 30108837]
    RAW264.7 CC50
    10 μM
    Compound: 1
    Cytotoxicity against BSO-treated mouse RAW264.7 cells assessed as reduction cell viability measured after 24 hrs by Celltiter-glo assay
    Cytotoxicity against BSO-treated mouse RAW264.7 cells assessed as reduction cell viability measured after 24 hrs by Celltiter-glo assay
    [PMID: 32712435]
    RAW264.7 IC50
    14.42 μM
    Compound: Andrographolide
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS addition measured after 24 hrs by Griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS addition measured after 24 hrs by Griess assay
    [PMID: 31009914]
    RAW264.7 IC50
    6.96 μM
    Compound: 21
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
    [PMID: 22264489]
    THP-1 IC50
    6.69 μM
    Compound: Andrographolide
    Antiproliferative activity against human THP1 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    Antiproliferative activity against human THP1 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    [PMID: 20974534]
    TZM CC50
    1696 μM
    Compound: 1, andro
    Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay
    Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay
    [PMID: 22858223]
    U-937 IC50
    12.87 μM
    Compound: Andrographolide
    Antiproliferative activity against human U937 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    Antiproliferative activity against human U937 cells assessed as growth inhibition after 48 hrs by MTS-PMS assay
    [PMID: 20974534]
    體外研究
    (In Vitro)

    穿心蓮內(nèi)酯 (AP) 濃度依賴(lài)性地抑制核因子 κB 受體激活劑配體 (RANKL) 介導(dǎo)的破骨細(xì)胞分化和骨吸收,并降低破骨細(xì)胞特異性標(biāo)志物的表達(dá)。穿心蓮內(nèi)酯通過(guò)共價(jià)修飾 p50 的還原 Cys62 抑制 TNFα 誘導(dǎo)的 NF-κB 活化,從而減輕炎癥,而不影響 IκBα 降解或 p50/p65 核易位。穿心蓮內(nèi)酯還抑制 ERK/MAPK 信號(hào)通路,而不影響 p38 或 JNK 信號(hào)。穿心蓮內(nèi)酯以濃度依賴(lài)性方式抑制 RAW 264.7 細(xì)胞的破骨細(xì)胞分化。穿心蓮內(nèi)酯以濃度依賴(lài)性方式抑制破骨細(xì)胞形成,且在 BMM 和 RAW 264.7 細(xì)胞中均無(wú)明顯細(xì)胞毒性作用。穿心蓮內(nèi)酯治療可顯著減少骨吸收面積。在用 2.5 μM 穿心蓮內(nèi)酯治療后,僅達(dá)到對(duì)照組中觀察到的約 30% 的骨吸收。用 10 μM 穿心蓮內(nèi)酯治療后,破骨細(xì)胞骨吸收幾乎完全被抑制[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    體內(nèi)研究
    (In Vivo)

    穿心蓮內(nèi)酯 (5 或 30?mg/kg) 治療可降低 LPS 引起的骨質(zhì)流失程度。此外,與 LPS 治療相比,穿心蓮內(nèi)酯略微增加了 BMD 和皮質(zhì)厚度。組織學(xué)檢查證實(shí)了穿心蓮內(nèi)酯對(duì) LPS 引起的骨質(zhì)流失的保護(hù)作用。LPS 注射會(huì)導(dǎo)致炎性骨質(zhì)侵蝕和 TRAP 陽(yáng)性破骨細(xì)胞數(shù)量增加[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    350.45

    Formula

    C20H30O5

    CAS 號(hào)
    性狀

    固體

    顏色

    White to off-white

    中文名稱(chēng)

    穿心蓮內(nèi)酯

    結(jié)構(gòu)分類(lèi)
    初始來(lái)源
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.

    儲(chǔ)存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn): 

    DMSO 中的溶解度 : 100 mg/mL (285.35 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響,請(qǐng)使用新開(kāi)封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.8535 mL 14.2674 mL 28.5347 mL
    5 mM 0.5707 mL 2.8535 mL 5.7069 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn):

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用;
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (7.13 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請(qǐng)依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (7.13 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

      2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。

    以下溶解方案,請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配,在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比; 如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶。

    • 方案 一

      請(qǐng)依序添加每種溶劑: 0.5% CMC-Na/saline water

      Solubility: 2 mg/mL (5.71 mM); 懸濁液; 超聲助溶

    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息:

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    由于實(shí)驗(yàn)過(guò)程有損耗,建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
    方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購(gòu)。 Tween 80,均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
    您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度,以下方案僅供參考,如有需要,請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
    連續(xù)給藥周期超過(guò)半月以上,請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.89%

    參考文獻(xiàn)
    Kinase Assay
    [1]

    In vitro osteoclastogenesis assays are preformed to examine the effects of Andrographolide on osteoclast differentiation. Bone marrow macrophages (BMM) cells are prepared. Briefly, cells extracted from the femur and tibiae of a 6-week-old C57/BL6 mouse are incubated in complete cell culture media and 30?ng/mL?M-CSF in a T-75?cm2 flask for proliferation. When changing the medium, the cells are washed in order to deplete residual stromal cells. After reaching 90% confluence, cells are washed with PBS three times and trypsinized for 30?min to harvest BMMs. Cells adhering to the bottom of the dish are classified as BMMs; these BMMs are plated in 96-well plates at a density of 8×103 cells per well in triplicate and incubated in a humidified incubator containing 5% CO2 at 37°C for 24?h. The cells are then treated with various concentrations of Andrographolide (0, 2.5, 5, or 10?μM) plus M-CSF (30?ng/mL) and RANKL (50?ng/mL). After 5 days, cells are fixed and stained for tartrate-resistant acid phosphatase (TRAP) activity. TRAP-positive multinucleated cells with more than five nuclei are counted as osteoclasts[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    Effects of Andrographolide on cell proliferation are determined with a CCK-8. BMMs are plated in 96-well plates at a density of 3×103 cells per well in triplicate. Twenty-four hours later, the cells are treated with increasing concentrations of Andrographolide (0, 2.5, 5, 10 or 20?μM) for 2 days. Next, 10?μL CCK-8 is added to each well, and the plates are then incubated at 37°C for an additional 2?h. The optical density (OD) is then measured with an ELX800 absorbance microplate reader at a wavelength of 450?nm (650?nm reference). The cell viability is calculated[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice[1]
    C57BL/6 mice (8 weeks old) are divided into four groups of seven mice each. Mice are injected i.p. with Andrographolide (5 or 30?mg/kg body weight) or PBS as a control 1 day before injection of LPS (5?μg/g body weight). Andrographolide or PBS is injected intraperitoneally every other day for 8 days. LPS is injected intraperitoneally on days one and four. All mice are killed 8 days after the initial LPS injection, and the left femurs of all animals are scanned with a high-resolution micro-CT at a resolution of 9?μm.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.8535 mL 14.2674 mL 28.5347 mL 71.3369 mL
    5 mM 0.5707 mL 2.8535 mL 5.7069 mL 14.2674 mL
    10 mM 0.2853 mL 1.4267 mL 2.8535 mL 7.1337 mL
    15 mM 0.1902 mL 0.9512 mL 1.9023 mL 4.7558 mL
    20 mM 0.1427 mL 0.7134 mL 1.4267 mL 3.5668 mL
    25 mM 0.1141 mL 0.5707 mL 1.1414 mL 2.8535 mL
    30 mM 0.0951 mL 0.4756 mL 0.9512 mL 2.3779 mL
    40 mM 0.0713 mL 0.3567 mL 0.7134 mL 1.7834 mL
    50 mM 0.0571 mL 0.2853 mL 0.5707 mL 1.4267 mL
    60 mM 0.0476 mL 0.2378 mL 0.4756 mL 1.1889 mL
    80 mM 0.0357 mL 0.1783 mL 0.3567 mL 0.8917 mL
    100 mM 0.0285 mL 0.1427 mL 0.2853 mL 0.7134 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱(chēng):

     

    * 需求量:

    * 客戶(hù)姓名:

     

    * Email:

    * 電話(huà):

     

    * 公司或機(jī)構(gòu)名稱(chēng):

       留言給我們:

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱(chēng):
    Andrographolide
    目錄號(hào):
    HY-N0191
    需求量: